217 related articles for article (PubMed ID: 17053970)
1. Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa-treated rats.
Ba M; Kong M; Yang H; Ma G; Lu G; Chen S; Liu Z
Neurochem Res; 2006 Nov; 31(11):1337-47. PubMed ID: 17053970
[TBL] [Abstract][Full Text] [Related]
2. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits.
Oh JD; Vaughan CL; Chase TN
Brain Res; 1999 Mar; 821(2):433-42. PubMed ID: 10064831
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of acute or chronic administration of levodopa to 6-OHDA-lesioned rats on the expression and phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in the striatum.
Kong M; Ba M; Song L; Liu Z
Neurochem Res; 2009 Aug; 34(8):1513-21. PubMed ID: 19283475
[TBL] [Abstract][Full Text] [Related]
4. Roles of Ca(2+)/calmodulin-dependent protein kinase II in subcellular expression of striatal N-methyl-D-aspartate receptors in l-3, 4-dihydroxyphenylalanine-induced dyskinetic rats.
Gan J; Qi C; Liu Z
Drug Des Devel Ther; 2015; 9():2119-28. PubMed ID: 25926720
[TBL] [Abstract][Full Text] [Related]
5. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
6. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
Wessell RH; Ahmed SM; Menniti FS; Dunbar GL; Chase TN; Oh JD
Neuropharmacology; 2004 Aug; 47(2):184-94. PubMed ID: 15223297
[TBL] [Abstract][Full Text] [Related]
7. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease.
Dunah AW; Wang Y; Yasuda RP; Kameyama K; Huganir RL; Wolfe BB; Standaert DG
Mol Pharmacol; 2000 Feb; 57(2):342-52. PubMed ID: 10648644
[TBL] [Abstract][Full Text] [Related]
8. GluR1 phosphorylation and persistent expression of levodopa-induced motor response alterations in the Hemi-Parkinsonian rat.
Ba M; Kong M; Yu G; Sun X; Liu Z; Wang X
Neurochem Res; 2011 Jun; 36(6):1135-44. PubMed ID: 21461922
[TBL] [Abstract][Full Text] [Related]
9. Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats.
Takuma K; Tanaka T; Takahashi T; Hiramatsu N; Ota Y; Ago Y; Matsuda T
Eur J Pharmacol; 2012 May; 683(1-3):166-73. PubMed ID: 22449381
[TBL] [Abstract][Full Text] [Related]
10. Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats.
Oh JD; Geller AI; Zhang Gr; Chase TN
Brain Res; 2003 May; 971(1):18-30. PubMed ID: 12691833
[TBL] [Abstract][Full Text] [Related]
11. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice.
Santini E; Alcacer C; Cacciatore S; Heiman M; Hervé D; Greengard P; Girault JA; Valjent E; Fisone G
J Neurochem; 2009 Feb; 108(3):621-33. PubMed ID: 19187092
[TBL] [Abstract][Full Text] [Related]
12. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
13. Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats.
Oh JD; Chartisathian K; Ahmed SM; Chase TN
J Neurosci Res; 2003 Jun; 72(6):768-80. PubMed ID: 12774317
[TBL] [Abstract][Full Text] [Related]
14. Gene expression of glutamate receptors GluR1 and NR1 is differentially modulated in striatal neurons in rats after 6-hydroxydopamine lesion.
Lai SK; Tse YC; Yang MS; Wong CK; Chan YS; Yung KK
Neurochem Int; 2003 Dec; 43(7):639-53. PubMed ID: 12892651
[TBL] [Abstract][Full Text] [Related]
15. AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.
Périer C; Marin C; Bonastre M; Tolosa E; Hirsch EC
Eur J Neurosci; 2002 Dec; 16(11):2236-40. PubMed ID: 12473092
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA.
Tomiyama M; Kimura T; Maeda T; Tanaka H; Kannari K; Baba M
Synapse; 2004 Jun; 52(3):218-22. PubMed ID: 15065221
[TBL] [Abstract][Full Text] [Related]
17. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
18. Memory consolidation induces N-methyl-D-aspartic acid-receptor- and Ca2+/calmodulin-dependent protein kinase II-dependent modifications in alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor properties.
Bevilaqua LR; Medina JH; Izquierdo I; Cammarota M
Neuroscience; 2005; 136(2):397-403. PubMed ID: 16182449
[TBL] [Abstract][Full Text] [Related]
19. The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats.
Song L; Yang X; Ma Y; Wu N; Liu Z
Drug Des Devel Ther; 2014; 8():2173-9. PubMed ID: 25395834
[TBL] [Abstract][Full Text] [Related]
20. CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
Yang X; Zhu Z; Ding X; Wang X; Cui G; Hua F; Xiang J
Brain Res; 2018 May; 1687():66-73. PubMed ID: 29452071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
